As of 2025-12-24, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 74.72 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 15.5x | 15.2x |
| Forward P/E multiples | 17.3x - 22.3x | 22.1x |
| Fair Price | (4.64) - (4.17) | (5.00) |
| Upside | -257760.9% - -231571.8% | -277623.3% |
| Date | EV/EBITDA |
| 2025-12-22 | -0.22 |
| 2025-12-19 | -0.22 |
| 2025-12-18 | -0.22 |
| 2025-12-17 | -0.22 |
| 2025-12-16 | -0.23 |
| 2025-12-15 | -0.23 |
| 2025-12-12 | -0.23 |
| 2025-12-11 | -0.23 |
| 2025-12-10 | -0.23 |
| 2025-12-09 | -0.23 |
| 2025-12-08 | -0.23 |
| 2025-12-05 | -0.23 |
| 2025-12-04 | -0.23 |
| 2025-12-03 | -0.23 |
| 2025-12-02 | -0.23 |
| 2025-12-01 | -0.23 |
| 2025-11-28 | -0.24 |
| 2025-11-26 | -0.23 |
| 2025-11-25 | -0.24 |
| 2025-11-24 | -0.23 |
| 2025-11-21 | -0.24 |
| 2025-11-20 | -0.23 |
| 2025-11-19 | -0.23 |
| 2025-11-18 | -0.23 |
| 2025-11-17 | -0.24 |
| 2025-11-14 | -0.25 |
| 2025-11-13 | -0.24 |
| 2025-11-12 | -0.25 |
| 2025-11-11 | -0.24 |
| 2025-11-10 | -0.24 |
| 2025-11-07 | -0.25 |
| 2025-11-06 | -0.25 |
| 2025-11-05 | -0.25 |
| 2025-11-04 | -0.25 |
| 2025-11-03 | -0.24 |
| 2025-10-31 | -0.24 |
| 2025-10-30 | -0.24 |
| 2025-10-29 | -0.24 |
| 2025-10-28 | -0.24 |
| 2025-10-27 | -0.24 |
| 2025-10-24 | -0.24 |
| 2025-10-23 | -0.23 |
| 2025-10-22 | -0.24 |
| 2025-10-21 | -0.24 |
| 2025-10-20 | -0.24 |
| 2025-10-17 | -0.24 |
| 2025-10-16 | -0.24 |
| 2025-10-15 | -0.24 |
| 2025-10-14 | -0.23 |
| 2025-10-13 | -0.23 |